Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma

Erik L. Brincks, Tamara A. Kucaba, Britnie R. James, Katherine A. Murphy, Kathryn L. Schwertfeger, Veena Sangwan, Sulagna Banerjee, Ashok K. Saluja, Thomas S. Griffith

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Renal cell carcinoma (RCC) is resistant to traditional cancer therapies, and metastatic RCC (mRCC) is incurable. The shortcomings in current therapeutic options for patients with mRCC provide the rationale for the development of novel treatment protocols. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has proven to be a potent inducer of tumor cell death in vitro and in vivo, and a number of TRAIL death receptor agonists (recombinant TRAIL or TRAIL death receptor-specific mAb) have been developed and tested clinically. Unfortunately the clinical efficacy of TRAIL has been underwhelming and is likely due to a number of possible mechanisms that render tumors resistant to TRAIL, prompting the search for drugs that increase tumor cell susceptibility to TRAIL. The objective of this study was to determine the effectiveness of combining the diterpene triepoxide triptolide, or its water-soluble prodrug, Minnelide, with TRAIL receptor agonists against RCC in vitro or in vivo, respectively. TRAIL-induced apoptotic death of human RCC cells was increased in the presence of triptolide. The triptolide-induced sensitization was accompanied by increased TRAIL-R2 (DR5) and decreased heat shock protein 70 expression. In vivo treatment of mice bearing orthotopic RCC (Renca) tumors showed the combination of Minnelide and agonistic anti-DR5 mAb significantly decreased tumor burden and increased animal survival compared to either therapy alone. Our data suggest triptolide/Minnelide sensitizes RCC cells to TRAIL-induced apoptosis through altered TRAIL death receptor and heat shock protein expression. TRAIL induces tumor cell death, but many cancers, including renal cell carcinoma (RCC), are resistant to TRAIL. Treatment of human and mouse RCC cells with the diterpene triepoxide, triptolide, effectively sensitizes these cells to TRAIL receptor agonists in vitro and in vivo. Triptolide sensitizes RCC cells to TRAIL by decreasing HSP70 expression and increasing TRAIL death receptor expression.

Original languageEnglish (US)
Pages (from-to)4747-4765
Number of pages19
JournalFEBS Journal
Issue number24
StatePublished - Dec 1 2015
Externally publishedYes


  • apoptosis
  • death receptor
  • renal cell carcinoma
  • triptolide

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma'. Together they form a unique fingerprint.

Cite this